Community activism in Brazil and Thailand compelled national governments to provide treatment to the HIV positive population, a decision facilitated by pharma companies, including many from India, cutting prices 40-fold. If quality and expensive care can be provided for one disease, then the same should be achievable for common diseases which require less expensive treatment.
